Category: RenalSyndicate content

Renal

TCT 2014: Another trial shows no benefit for renal denervation in hypertension

September 17, 2014 by Brad Perriello

Another trial of Medtronic's Symplicity renal denervation device in treating hypertension shows no benefit compared with a sham procedure.

TCT 2014: Another Medtronic trial shows no benefit for renal denervation in hypertension

Study: CardioMEMs implanted heart monitor safe for renal failure patients

September 16, 2014 by Arezu Sarvestani

New data from CardioMEMs CHAMPION clinical trial shows that the company's implanted pulmonary artery pressure monitor helps reduce heart failure hospitalizations without compromising kidney function in patients with renal failure.

Study: CardioMEMS' implanted sensor safe for renal failure patients

St. Jude Medical (NYSE:STJ) subsidiary CardioMEMs touted new study results this week showing that its implanted heart monitor is safe and effective in patients with chronic kidney disease.

TCT 2014: Is renal denervation dead or alive?

September 15, 2014 by Brad Perriello

Is renal denervation for hypertension dead or alive? Experts agree that more studies are needed.

TCT 2014: Is renal denervation dead or alive?

The efficacy of renal denervation is in doubt and should be confirmed or ruled out in treating resistant hypertension, according to an expert panel in a debate over the once high-flying technology at the Transcatheter Cardiovascular Therapeutics conference in Washington.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medtronic's renal denervation no better at 1 year, researchers say

September 5, 2014 by Arezu Sarvestani

Medtronic's failed Symplicity HTN-3 renal denervation study doesn't look any better with 12 months of follow-up, according to new results presented at this year's European Society of Cardiology Congress.

Medtronic's renal denervation no better at 1 year, study finds

Renal denervation technologies took another blow this week as 1-year results from Medtronic's (NYSE:MDT) much-lamented Symplicity HTN-3 trial still turned out no signs that the treatment is effective against hypertension.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Renal denervation isn't dead, despite Medtronic trial's failure

September 2, 2014 by Brad Perriello

The failure of Medtronic's Symplicity 3 trial doesn't mean the end of renal denervation in treated resistant hypertension, especially in Europe, but future studies face a high bar set by the Medtronic trial's sham control arm.

Renal denervation isn't dead, despite Medtronic trial's failure

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Kona Medical launches hypertension trial for non-invasive RDN device

August 29, 2014 by Brad Perriello

Kona Medical announces the launch of a clinical trial for its non-invasive Surround Sound renal denervation device for treating hypertension.

Kona Medical launches hypertension trial for non-invasive RDN device

Kona Medical said this week that it's launched a clinical trial of the non-invasive renal denervation device for treating hypertension it calls Surround Sound.

Simple, not sexy: Twitter docs weigh in on the future of renal denervation

May 28, 2014 by Arezu Sarvestani

Twitter-savvy physicians and researchers mull over the latest clinical results for Medtronic's renal denervation technology, calling for more common sense and less hype in treating hypertension.

Simple, not sexy: Twitter's docs weigh in on the future of renal denervation
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp